Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048965 | 0.85 | OPRM1 (0.36) | CACNA2D1 | |
| SCHEMBL2873412 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL2873409 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL10076041 | 0.78 | CHEK1 (0.36) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL12949686 | 0.76 | NR1I2 (0.39) | — | |
| SCHEMBL2431371 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL2431376 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL13630959 | 0.72 | ALDH1A1 (0.43) | SLC6A4SLC6A2 | |
| SCHEMBL1077272 | 0.71 | NR1I2 (0.36) | — | |
| SCHEMBL2106809 | 0.71 | NR1I2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CACNA2D1 4753/4885SLC6A4 1697/4885SLC6A2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.